Comparison of mean log efavirenz plasma concentrations at week 4 and week 16 of efavirenz therapy between Ethiopian and Tanzanian HIV patients having the same CYP2B6*6 genotype.

Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz:the effect of gender, race, and CYP2B6 polymorphism

Burger, D
van der Heiden, [No Value]
la Porte, C
van der Ende, Marchina E.
Groeneveld, P
Richter, C
Koopmans, P
Sprenger, H
Lindemans, J
Schenk, P
van Schaik, R

February 2006

Aims To characterize the demographic and pharmacogenetic factors that influence interpatient variabi...

Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes.

Jackson K Mukonzo
Joel S Owen
Jasper Ogwal-Okeng
Ronald B Kuteesa
Sarah Nanzigu
Nelson Sewankambo
Lehana Thabane
Lars L Gustafsson
Colin Ross
Eleni Aklillu

Pharmacogenetics contributes to inter-individual variability in pharmacokinetics (PK) of efavirenz (...

Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study

Dickinson, L
Amin, J
Else, L
Boffito, M
Egan, D
Owen, A
Khoo, S
Back, D
Orrell, C
Clarke, A
Losso, M
Phanuphak, P
Carey, D
Cooper, DA
Emery, S
Puls, R

October 2015

Daily efavirenz 400 mg (EFV400) was virologically noninferior to 600 mg (EFV600) at 48 weeks in trea...

Comparison of mean ± SE of mean efavirenz plasma concentration on the 4th and 16th weeks after initiation of efavirenz based HAART separately between Ethiopian and Tanzanian patients using independent t test.

Eliford Ngaimisi (316246)
Abiy Habtewold (338191)
Omary Minzi (316248)
Eyasu Makonnen (157087)
Sabina Mugusi (316245)
Wondwossen Amogne (338194)
Getnet Yimer (338188)
Klaus-Dieter Riedel (316250)
Mohammed Janabi (431118)
Getachew Aderaye (338201)
Ferdinand Mugusi (214835)
Leif Bertilsson (431119)
Eleni Aklillu (316254)
Juergen Burhenne (316251)

July 2013

Comparison of efavirenz concentration between week 4 and week 16 with in Ethiopians and Tanzanian...

Plasma efavirenz concentrations of 171 HIV-infected patients with different genotypes of CYP2B6 G516T polymorphisms.

Kuan-Yeh Lee (523493)
Shu-Wen Lin (523494)
Hsin-Yun Sun (61134)
Ching-Hua Kuo (523495)
Mao-Song Tsai (523496)
Bing-Ru Wu (523497)
Sue-Yo Tang (523498)
Wen-Chun Liu (61140)
Sui-Yuan Chang (39460)
Chien-Ching Hung (61132)

February 2014

Dash lines indicate the target plasma concentrations of efavirenz for wild-type HIV-1 isolate.</p

Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations

Ngaimisi, E
Habtewold, A
Minzi, O
Makonnen, E
Mugusi, S
Amogne, W
Yimer, G
Riedel, K
Janabi, M
Aderaye, G
Mugusi, F
Bertilsson, L
Aklillu, E
Burhenne, J

January 2013

Objectives: We evaluated the importance of ethnicity and pharmacogenetic variations in determining e...

Importance of Ethnicity, CYP2B6 and ABCB1 Genotype for Efavirenz Pharmacokinetics and Treatment Outcomes: A Parallel-Group Prospective Cohort Study in Two Sub-Saharan Africa Populations

Ngaimisi Eliford
Habtewold Abiy
Minzi Omary
Makonnen Eyasu
Mugusi Sabina
Amogne Wondwossen
Yimer Getnet
Riedel Klaus-Dieter
Janabi Mohammed
Aderaye Getachew
Mugusi Ferdinand
Bertilsson Leif
Aklillu Eleni
Burhenne Juergen

July 2013

We evaluated the importance of ethnicity and pharmacogenetic variations in determining efavirenz pha...

Prediction of plasma efavirenz concentrations among HIV-positive patients taking efavirenz-containing combination antiretroviral therapy

Huang, Sung-Hsi

May 2022

We investigated the predictors of plasma mid-dose concentrations (C12) of efavirenz by enrolling 456...

Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals.

Arab-Alameddine, M.
Di Iulio, J.
Buclin, T.
Rotger, M.
Lubomirov, R.
Cavassini, M.
Fayet, A.
Décosterd, L.A.
Eap, C.B.
Biollaz, J.
Telenti, A.
Csajka, C.

January 2009

Besides CYP2B6, other polymorphic enzymes contribute to efavirenz (EFV) interindividual variability....

Predictive value of known and novel alleles ofCYP2B6 for efavirenz plasma concentrations in HIV-infected individuals

Rotger, M.
Tegude, H.
Colombo, S.
Cavassini, M.
Furrer, H.
Decosterd, L.
Blievernicht, J.
Saussele, T.
Gunthard, H.
Schwab, M.
Eichelbaum, M.
Telenti, A.
Zanger, U.

January 2007

Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals

Rotger, M.
Tegude, H.
Colombo, S.
Cavassini, M.
Furrer, H.
Decosterd, L.
Blievernicht, J.
Saussele, T.
Gunthard, H. F.
Schwab, M.
Eichelbaum, M.
Telenti, A.
Zanger, U. M.

April 2007

To assess the association of CYP2B6 allelic diversity with efavirenz (EFV) pharmacokinetics, we perf...

Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism.

Burger, D.M.
Heiden, I. van der
Porte, C.J.L. la
Ende, M. van der
Groeneveld, P.
Richter, C.
Koopmans †, P.P.
Kroon, F.
Sprenger, H.
Lindemans, J.
Schenk, P.
Schaik, R. van

January 2006

AIMS: To characterize the demographic and pharmacogenetic factors that influence interpatient variab...

Pharmacogenetic-Based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes

Mukonzo Jackson K.
Owen Joel S.
Ogwal-Okeng Jasper
Kuteesa Ronald B.
Nanzigu Sarah
Sewankambo Nelson
Thabane Lehana
Gustafsson Lars L.
Ross Colin
Aklillu Eleni

January 2014

Pharmacogenetics contributes to inter-individual variability in pharmacokinetics (PK) of efavirenz (...

Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals

Arab-Alameddine, M.
Di Iulio, J.
Buclin, Thierry
Rotger, M.
Lubomirov, R.
Cavassini, M.
Fayet, A.
Decosterd, L. A.
Eap, Chin Bin
Biollaz, J.
Telenti, A.
Csajka, C.

January 2009

Besides CYP2B6, other polymorphic enzymes contribute to efavirenz (EFV) interindividual variability....

Mid-Dosing Interval Efavirenz Plasma Concentrations in HIV-1-Infected Children in Rwanda: Treatment Efficacy, Tolerability, Adherence, and the Influence of CYP2B6 Polymorphisms

Mutwa, PR
Fillekes, Q
Malgaz, M
Tuyishimire, D
van der Kraats, R (Rianne)
Boer, KR
Burger, DM
van Schaik, Ron
Muganga, N
Geelen, SPM

January 2012

This study evaluated mid-dosing interval efavirenz plasma concentrations and the influence of CYP2B6...

Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz:the effect of gender, race, and CYP2B6 polymorphism

Burger, D
van der Heiden, [No Value]
la Porte, C
van der Ende, Marchina E.
Groeneveld, P
Richter, C
Koopmans, P
Sprenger, H
Lindemans, J
Schenk, P
van Schaik, R

February 2006

Aims To characterize the demographic and pharmacogenetic factors that influence interpatient variabi...

Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes.

Jackson K Mukonzo
Joel S Owen
Jasper Ogwal-Okeng
Ronald B Kuteesa
Sarah Nanzigu
Nelson Sewankambo
Lehana Thabane
Lars L Gustafsson
Colin Ross
Eleni Aklillu

Pharmacogenetics contributes to inter-individual variability in pharmacokinetics (PK) of efavirenz (...

Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study

Dickinson, L
Amin, J
Else, L
Boffito, M
Egan, D
Owen, A
Khoo, S
Back, D
Orrell, C
Clarke, A
Losso, M
Phanuphak, P
Carey, D
Cooper, DA
Emery, S
Puls, R

October 2015

Daily efavirenz 400 mg (EFV400) was virologically noninferior to 600 mg (EFV600) at 48 weeks in trea...

Comparison of mean ± SE of mean efavirenz plasma concentration on the 4th and 16th weeks after initiation of efavirenz based HAART separately between Ethiopian and Tanzanian patients using independent t test.

Eliford Ngaimisi (316246)
Abiy Habtewold (338191)
Omary Minzi (316248)
Eyasu Makonnen (157087)
Sabina Mugusi (316245)
Wondwossen Amogne (338194)
Getnet Yimer (338188)
Klaus-Dieter Riedel (316250)
Mohammed Janabi (431118)
Getachew Aderaye (338201)
Ferdinand Mugusi (214835)
Leif Bertilsson (431119)
Eleni Aklillu (316254)
Juergen Burhenne (316251)

July 2013

Comparison of efavirenz concentration between week 4 and week 16 with in Ethiopians and Tanzanian...

Plasma efavirenz concentrations of 171 HIV-infected patients with different genotypes of CYP2B6 G516T polymorphisms.

Kuan-Yeh Lee (523493)
Shu-Wen Lin (523494)
Hsin-Yun Sun (61134)
Ching-Hua Kuo (523495)
Mao-Song Tsai (523496)
Bing-Ru Wu (523497)
Sue-Yo Tang (523498)
Wen-Chun Liu (61140)
Sui-Yuan Chang (39460)
Chien-Ching Hung (61132)

February 2014

Dash lines indicate the target plasma concentrations of efavirenz for wild-type HIV-1 isolate.</p

Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations

Ngaimisi, E
Habtewold, A
Minzi, O
Makonnen, E
Mugusi, S
Amogne, W
Yimer, G
Riedel, K
Janabi, M
Aderaye, G
Mugusi, F
Bertilsson, L
Aklillu, E
Burhenne, J

January 2013

Objectives: We evaluated the importance of ethnicity and pharmacogenetic variations in determining e...

Importance of Ethnicity, CYP2B6 and ABCB1 Genotype for Efavirenz Pharmacokinetics and Treatment Outcomes: A Parallel-Group Prospective Cohort Study in Two Sub-Saharan Africa Populations

Ngaimisi Eliford
Habtewold Abiy
Minzi Omary
Makonnen Eyasu
Mugusi Sabina
Amogne Wondwossen
Yimer Getnet
Riedel Klaus-Dieter
Janabi Mohammed
Aderaye Getachew
Mugusi Ferdinand
Bertilsson Leif
Aklillu Eleni
Burhenne Juergen

July 2013

We evaluated the importance of ethnicity and pharmacogenetic variations in determining efavirenz pha...

Prediction of plasma efavirenz concentrations among HIV-positive patients taking efavirenz-containing combination antiretroviral therapy

Huang, Sung-Hsi

May 2022

We investigated the predictors of plasma mid-dose concentrations (C12) of efavirenz by enrolling 456...

Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals.

Arab-Alameddine, M.
Di Iulio, J.
Buclin, T.
Rotger, M.
Lubomirov, R.
Cavassini, M.
Fayet, A.
Décosterd, L.A.
Eap, C.B.
Biollaz, J.
Telenti, A.
Csajka, C.

January 2009

Besides CYP2B6, other polymorphic enzymes contribute to efavirenz (EFV) interindividual variability....

Predictive value of known and novel alleles ofCYP2B6 for efavirenz plasma concentrations in HIV-infected individuals

Rotger, M.
Tegude, H.
Colombo, S.
Cavassini, M.
Furrer, H.
Decosterd, L.
Blievernicht, J.
Saussele, T.
Gunthard, H.
Schwab, M.
Eichelbaum, M.
Telenti, A.
Zanger, U.

January 2007

Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals

Rotger, M.
Tegude, H.
Colombo, S.
Cavassini, M.
Furrer, H.
Decosterd, L.
Blievernicht, J.
Saussele, T.
Gunthard, H. F.
Schwab, M.
Eichelbaum, M.
Telenti, A.
Zanger, U. M.

April 2007

To assess the association of CYP2B6 allelic diversity with efavirenz (EFV) pharmacokinetics, we perf...

Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism.

Burger, D.M.
Heiden, I. van der
Porte, C.J.L. la
Ende, M. van der
Groeneveld, P.
Richter, C.
Koopmans †, P.P.
Kroon, F.
Sprenger, H.
Lindemans, J.
Schenk, P.
Schaik, R. van

January 2006

AIMS: To characterize the demographic and pharmacogenetic factors that influence interpatient variab...

Pharmacogenetic-Based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes

Mukonzo Jackson K.
Owen Joel S.
Ogwal-Okeng Jasper
Kuteesa Ronald B.
Nanzigu Sarah
Sewankambo Nelson
Thabane Lehana
Gustafsson Lars L.
Ross Colin
Aklillu Eleni

January 2014

Pharmacogenetics contributes to inter-individual variability in pharmacokinetics (PK) of efavirenz (...

Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals

Arab-Alameddine, M.
Di Iulio, J.
Buclin, Thierry
Rotger, M.
Lubomirov, R.
Cavassini, M.
Fayet, A.
Decosterd, L. A.
Eap, Chin Bin
Biollaz, J.
Telenti, A.
Csajka, C.

January 2009

Besides CYP2B6, other polymorphic enzymes contribute to efavirenz (EFV) interindividual variability....

Mid-Dosing Interval Efavirenz Plasma Concentrations in HIV-1-Infected Children in Rwanda: Treatment Efficacy, Tolerability, Adherence, and the Influence of CYP2B6 Polymorphisms

Mutwa, PR
Fillekes, Q
Malgaz, M
Tuyishimire, D
van der Kraats, R (Rianne)
Boer, KR
Burger, DM
van Schaik, Ron
Muganga, N
Geelen, SPM

January 2012

This study evaluated mid-dosing interval efavirenz plasma concentrations and the influence of CYP2B6...

Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz:the effect of gender, race, and CYP2B6 polymorphism

Burger, D
van der Heiden, [No Value]
la Porte, C
van der Ende, Marchina E.
Groeneveld, P
Richter, C
Koopmans, P
Sprenger, H
Lindemans, J
Schenk, P
van Schaik, R

February 2006

Aims To characterize the demographic and pharmacogenetic factors that influence interpatient variabi...

Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes.

Jackson K Mukonzo
Joel S Owen
Jasper Ogwal-Okeng
Ronald B Kuteesa
Sarah Nanzigu
Nelson Sewankambo
Lehana Thabane
Lars L Gustafsson
Colin Ross
Eleni Aklillu

Pharmacogenetics contributes to inter-individual variability in pharmacokinetics (PK) of efavirenz (...

Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study

Dickinson, L
Amin, J
Else, L
Boffito, M
Egan, D
Owen, A
Khoo, S
Back, D
Orrell, C
Clarke, A
Losso, M
Phanuphak, P
Carey, D
Cooper, DA
Emery, S
Puls, R

October 2015

Daily efavirenz 400 mg (EFV400) was virologically noninferior to 600 mg (EFV600) at 48 weeks in trea...

Comparison of mean log efavirenz plasma concentrations at week 4 and week 16 of efavirenz therapy between Ethiopian and Tanzanian HIV patients having the same <i>CYP2B6*6</i> genotype.

Abstract

Extracted data

Comparison of mean log efavirenz plasma concentrations at week 4 and week 16 of efavirenz therapy between Ethiopian and Tanzanian HIV patients having the same <i>CYP2B6*6</i> genotype.

Abstract

Extracted data

Related items

Related items